BUZZ-Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes

Reuters11-19

** Shares of Syros Pharmaceuticals SYRS.O down 24.1% at $0.20, trading at an all-time low

** Co terminates its partnership with QIAGEN Manchester Limited after a clinical trial for its blood cancer treatment, tamibarotene, failed to meet its main goal

** Implements reduction in workforce by about 94%

** In connection with the workforce reduction, CEO Conley Chee and CFO Jason Haas will be terminated without cause, effective Nov. 22

** SYRS appoints Gerald Quirk as president and CEO

** Including session's gains, stock has fallen 97.4% YTD

(Reporting by Nithyashree R B)

((NithyashreeRB@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484888099?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-19 03:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484888099","market":"us","top_or_hot":-1,"title":"BUZZ-Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes</title></head><body><p>** Shares of Syros Pharmaceuticals <span>SYRS.O</span> down 24.1% at $0.20, trading at an all-time low</p><p>** Co terminates its partnership with QIAGEN Manchester Limited after a clinical trial for its blood cancer treatment, tamibarotene, failed to meet its main goal</p><p>** Implements reduction in workforce by about 94%</p><p>** In connection with the workforce reduction, CEO Conley Chee and CFO Jason Haas will be terminated without cause, effective Nov. 22</p><p>** SYRS appoints Gerald Quirk as president and CEO</p><p>** Including session's gains, stock has fallen 97.4% YTD</p><p> (Reporting by Nithyashree R B)</p><p> ((NithyashreeRB@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 03:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4N3MP1CN:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes** Shares of Syros Pharmaceuticals SYRS.O down 24.1% at $0.20, trading at an all-time low** Co terminates ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4N3MP1CN:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2125909247.SGD","symbol_name":"Natixis Thematics Meta H-R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4N3MP1CN:1","article_id":"2484888099","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484888099","pubTimestamp":1731959004,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes** Shares of Syros Pharmaceuticals SYRS.O down 24.1% at $0.20, trading at an all-time low** Co terminates its partnership with QIAGEN Manchester Limited after a clinical trial for its blood cancer treatment, tamibarotene, failed to meet its main goal** Implements reduction in workforce by about 94%** In connection with the workforce reduction, CEO Conley Chee and CFO Jason Haas will be terminated without cause, effective Nov. 22** SYRS appoints Gerald Quirk as president and CEO** Including session's gains, stock has fallen 97.4% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","QGEN":"快而精医药","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","BK4121":"生命科学工具和服务","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","BK4139":"生物科技","SYRS":"Syros Pharmaceuticals Inc."},"translate_title":"BUZZ-Syros Pharmaceuticals因QIAGEN交易终止和领导层变动而创下历史新低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":0.9,"SYRS":0.9},"content_text":"BUZZ-Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes** Shares of Syros Pharmaceuticals SYRS.O down 24.1% at $0.20, trading at an all-time low** Co terminates its partnership with QIAGEN Manchester Limited after a clinical trial for its blood cancer treatment, tamibarotene, failed to meet its main goal** Implements reduction in workforce by about 94%** In connection with the workforce reduction, CEO Conley Chee and CFO Jason Haas will be terminated without cause, effective Nov. 22** SYRS appoints Gerald Quirk as president and CEO** Including session's gains, stock has fallen 97.4% YTD (Reporting by Nithyashree R B) ((NithyashreeRB@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"Executive Changes","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484888099"}